Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.

@article{Leboulleux2012VandetanibIL,
  title={Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.},
  author={Sophie Leboulleux and Lars Bastholt and Thomas Krause and Christelle de la Fouchardi{\`e}re and Jan G Tennvall and Ahmad Awada and Jos{\'e} Manuel G{\'o}mez and Françoise Bonichon and Laurence Leenhardt and Christine Soufflet and Muriel Licour and Martin Jean Schlumberger},
  journal={The Lancet. Oncology},
  year={2012},
  volume={13 9},
  pages={897-905}
}
BACKGROUND No effective standard treatment exists for patients with radioiodine-refractory, advanced differentiated thyroid carcinoma. We aimed to assess efficacy and safety of vandetanib, a tyrosine kinase inhibitor of RET, VEGFR and EGFR signalling, in this setting. METHODS In this randomised, double-blind, phase 2 trial, we enrolled adults (aged ≥18 years) with locally advanced or metastatic differentiated thyroid carcinoma (papillary, follicular, or poorly differentiated) at 16 European… CONTINUE READING